Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

If you have received the AstraZeneca Covishield vaccine, it is important to consider getting tested for Thrombosis with Thrombocytopenia Syndrome | Comprehensive Guide | Health and Wellness

Reading Time: 2 minutes

In a groundbreaking revelation, AstraZeneca has admitted that its Covid-19 vaccine may result in a rare side effect called Thrombosis with Thrombocytopenia Syndrome (TTS). This acknowledgment comes in the midst of a lawsuit filed against the company, alleging severe harm and fatalities linked to the vaccine.

The lawsuit highlights mounting apprehensions surrounding Covishield, a vaccine co-developed by AstraZeneca and Oxford University and produced by the Serum Institute of India. Covishield was extensively distributed across India during the peak of the Covid-19 crisis, prompting concerns about its safety profile.

Thrombosis with Thrombocytopenia Syndrome (TTS) is a rare medical condition characterized by the formation of blood clots in unusual locations in the body, along with a decrease in platelet count. Platelets are vital for blood clotting, so a diminished count can pose significant health risks. TTS has been observed in individuals who have received adenoviral vector Covid-19 vaccines, including Vaxzevria, Covishield, and the Johnson & Johnson/Janssen vaccine. This syndrome is believed to arise from an immune response triggered by the vaccine, leading to the production of antibodies targeting a specific blood clotting protein.

The Centers for Disease Control and Prevention (CDC) classifies TTS into two tiers based on symptom severity and associated risks. Tier 1 involves rare blood clots in critical locations like the brain or gastrointestinal tract, often accompanied by typical clots in the legs or lungs. Tier 2 includes more common blood clots in the legs or lungs with a low platelet count. Symptoms of TTS can range from severe headaches and abdominal pain to difficulty breathing and cognitive impairment. Immediate medical attention is crucial for individuals experiencing these symptoms post-vaccination to rule out TTS and receive appropriate care. Public awareness of rare side effects like TTS is essential for informed decision-making and ensuring the ongoing safety and efficacy of vaccination efforts.

Taylor Swifts New Album Release Health issues from using ACs Boston Marathon 2024 15 Practical Ways To Save Money